Navigation Links
Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Date:6/19/2013

emissions lasting in excess of two years in the great majority of patients treated."  

Study participants were enrolled selected to receive either ibrutinib 420 mg (n=51) or 840 mg (n=34) as a once-daily, oral monotherapy. Both doses were associated with overall response rates of 71 percent. Del17p patients had an overall response rate of 68 percent. Two patients in the 420 mg dose arm had complete responses and 34 patients had partial responses. Across all relapsed or refractory patients, including the high risk patients, the estimated progression-free survival at 26 months was 75 percent. An additional 20 percent of patients treated with the 420 mg dose and 15 percent of patients taking the 840 mg dose achieved a partial response accompanied by lymphocytosis, an elevated blood lymphocyte count.

The majority of adverse events (AEs) observed in the study were considered to be Grade 1 or 2 in severity, including diarrhea, infections and fatigue. A total of six patients taking ibrutinib experienced an AE leading them to discontinue treatment with the drug. Severe AEs observed during the treatment period include pneumonia and dehydration (12 percent and six percent, respectively), as well anemia, neutropenia and thrombocytopenia (six percent, 15 percent and six percent, respectively). Grade 3-4 hematological toxicities were not common.

Data from this study were presented at the annual meeting of the American Society of Hematology in December 2012.

Study Design
The Phase 1b/2, open-label, multicenter study was designed to determine the safety, efficacy, pharmacokinetics and pharmacodynamics of ibrutinib in patients with relapsed or refractory CLL. The primary objective of the study was to determine the safety of the two fixed-dose regimens of ibrutinib, assessed by evaluating the frequency and severity of AEs. Secondary efficacy endpoints included: overall response rate, progression-free survival and an exploratory endpoint of overa
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 In today,s rapidly changing, highly ... tools are essential for survival. The world is ... desires, preferences, and unmet needs are evolving rapidly. ... across all industries are continually searching for innovative ... adoption of new market research techniques like mobile ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 /PRNewswire/ ...  Sorrento), an oncology company developing new treatments for ... privately-held immuno-oncology company developing proprietary Neukoplast ® ... announced today that the companies have entered into ... CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the treatment ...
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... meals, addressing hearing health was forgotten. But Audicus ... resolve to hear better this new year. ... condition facing the aging population, though it is often ... one in four has a hearing aid, mainly due ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Audicus Will Help People Resolve to Hear Better in 2015 2
... solutions in ... developing countries, SEATTLE, Jan. 22 ... Venkayya has joined the Global Health,Program as director of Global Health ... government medical and public health,efforts, including preparations for a potential influenza ...
... Israel, Jan. 22 Protalix,BioTherapeutics, Inc. (Amex: ... of concept results in an animal study conducted ... (AChE),Program is being conducted under the agreement the ... Company, the technology transfer,arm of the Hebrew University ...
Cached Medicine Technology:Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery 2Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 2Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 3
(Date:12/22/2014)... Super Saturday, the last Saturday before ... the busiest day in the 2014 holiday shopping season. ... had a steady pre-Christmas stream of customers, ready to ... , “I definitely intend to take advantage…of the recreational ... who was enjoying The Grass Station’s holiday sale on ...
(Date:12/22/2014)... Give a loved one the greatest gift of ... vitality. , For a limited time, HealthiPlus ( https://healthiplus.com/christmas-gift-packages/ ... special Holiday Wellness gift packages at drastically reduced prices ... contains cutting-edge, proven nutritional support for joints, mental functioning ... we age. , Joint Health Plus contains ...
(Date:12/22/2014)... 2014 Pasadena sleep apnea ... sleep apnea. Drowsy drivers are 15 times more likely ... well-rested, and some experts believe that sleep-deprived drivers may ... drivers. Unfortunately, millions of Americans may be sleep-deprived without ... Sleep Medicine, about 18 million Americans have sleep apnea, ...
(Date:12/22/2014)... 2014 TheHardwareCity.com now stocks MagnoGrip Pro ... useful features. Customers of the large online tool shop ... gloves delivered to their home or workplace with free ... that incorporate heavy duty magnets, which make work easier. ... to store metal parts on the back of their ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 NAPW ... 2014 Professional Woman of the Year. Ms. Foley is ... As the largest, most-recognized networking organization of professional women ... the National Association of Professional Women is a powerfully ... 300 Local Chapters. , “As a nurse, I felt ...
Breaking Medicine News(10 mins):Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2
... , NEWPORT NEWS, Va., Dec. 21 ... Food and Drug Administration (FDA) has granted 510(k) ... biopsy guidance. , GammaLoc(®), pronounced "gamma-loke", ... the Dilon 6800(®) Gamma Camera. The GammaLoc(®) (GL) ...
... , , NORTHBROOK, Ill., Dec. 21 ... quality and safety, announced today a new certification program to ... with new, stricter low lead requirements that will be mandatory ... Assembly Bill 1953 (AB 1953), now a state law, was ...
... , NEW YORK, Dec. 21 Today, Equinox Fitness ... Yoga, a luminous playground from Hong Kong where many practices ... is quite simply that. An aah-inspiring return to the authentic ... minimalist luxury. The result is an accessible and immersive experience ...
... , , JERUSALEM, Israel, ... a developer,of alternative drug delivery systems, announced today that Dr ... Oramed,s Oral Insulin,capsule. Dr. Eldor is the principal investigator for ... is a physician in the,Diabetes Unit and Endocrinology Department of ...
... 21 The Ensign Group, Inc. (Nasdaq: ENSG ) announced ... dividend of $0.05 per share of Ensign common stock, which is ... share. The dividend, which was unanimously approved by the Board on ... to shareholders of record as of December 31, 2009. , ...
... ... new organization trying to give the gift of life this holiday season by highlighting lack ... cancer killer for women and men yet receives least funds for research because lung cancer ... ...
Cached Medicine News:Health News:Dilon Diagnostics Gamma-Guided Localization System Cleared by FDA 2Health News:Underwriters Laboratories Announces Alternative Certification Program for Lead Free Verification of Cooking and Plumbing Products 2Health News:Equinox Introduces its Second Pure Yoga Studio on the Upper West Side 2Health News:Equinox Introduces its Second Pure Yoga Studio on the Upper West Side 3Health News:Oramed's Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel. 2Health News:Oramed's Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel. 3Health News:Exposing the Double Standard of the Forgotten Cancer: Biggest Cancer Killer for Women and Men, Lung Cancer, Receives Least Research Funds 2Health News:Exposing the Double Standard of the Forgotten Cancer: Biggest Cancer Killer for Women and Men, Lung Cancer, Receives Least Research Funds 3
... (gadopentetate dimeglumine) injection was introduced in 1988, ... contrast-enhanced magnetic resonance imaging (MRI). It became ... in MRI. Today, the product is still ... head, neck and body. MAGNEVIST is used ...
... injection is a nonionic, iodinated, low-osmolar ... Introduced in the U.S. in 1995, ... Europe, ULTRAVIST today is used ... established a positive clinical experience in ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
Forceps with round handle, straight...
Medicine Products: